Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ifinatamab deruxtecan (DS-7300)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Daiichi Sankyo, Merck (MSD)

Drug class:

Topoisomerase I inhibitor, B7-H3-targeted antibody-drug conjugate

Related drugs:

fam-trastuzumab deruxtecan-nxki (90)

irinotecan (48)

sacituzumab govitecan-hziy (17)

datopotamab deruxtecan (11)

HRA00129-C004 (3)

sacituzumab tirumotecan (3)

nanoliposomal irinotecan (3)

camptothecin nanosomal (1)

PF-08046044 (1)

rinatabart sesutecan (1)

HA-irinotecan (0)

ICAM‑1 ADC (0)

etirinotecan pegol (0)

irinotecan liposomal (0)

topotecan episcleral (0)

›

CD276 overexpression	Solid Tumor	CD276 overexpression	Solid Tumor	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3
CD276 overexpression	Prostate Cancer	CD276 overexpression	Prostate Cancer	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3
CD276 overexpression	Small Cell Lung Cancer	CD276 overexpression	Small Cell Lung Cancer	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3
CD276 overexpression	Non Small Cell Lung Cancer	CD276 overexpression	Non Small Cell Lung Cancer	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3
CD276 overexpression	Esophageal Squamous Cell Carcinoma	CD276 overexpression	Esophageal Squamous Cell Carcinoma	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3